Analytical Inclusivity of Three Commercial Real-Time PCR Platforms Against Carbapenemase Allelic Variants in Peruvian Clinical Isolates

Objectives: Rapid molecular detection of carbapenemase-producing Gram-negative bacilli is crucial for targeted antimicrobial therapy, but regional gene sequence diversity can impair commercial PCR assays. This study evaluated the analytical inclusivity of three commercial real-time PCR platforms (Xpert Carba-R on the GeneXpert system, Galaxy Lite, and Molecular Mouse) against carbapenemase alleles circulating in Peru, including the regionally relevant blaIMP-74 and blaIMP-93 alleles. Methods: We analyzed a positive-enriched challenge panel of 23 non-duplicate clinical isolates previously characterized by whole-genome sequencing (WGS): 10 Enterobacterales and 13 Pseudomonas aeruginosa carrying 26 carbapenemase genes across 12 variants (blaKPC-2/35, blaNDM-1/5, blaOXA-48/181/232, blaVIM-2, and blaIMP-16/18/74/93); inclusivity was calculated per WGS-confirmed target gene, and Molecular Mouse was evaluated on a 16-target subset including at least one representative of each allele. Results: Galaxy Lite detected all carbapenemase alleles evaluated (12/12 alleles; gene-level analytical inclusivity 100%, 26/26 target genes, 95% CI: 86.8–100%). Xpert Carba-R and Molecular Mouse each detected 8 of the 12 alleles (100% of KPC, NDM, OXA-48-like, and VIM alleles), failing to detect any of the four IMP alleles evaluated. Overall gene-level inclusivity was 53.8% (14/26 target genes, 95% CI: 33.4–73.4%) for Xpert Carba-R and 62.5% (10/16 target genes, 95% CI: 35.4–84.8%) for Molecular Mouse. Conclusions: In this small, positive-enriched panel, two of the three commercial PCR panels did not detect the IMP alleles tested, a finding that may be related to primer/probe–target sequence divergence, although this mechanism was not investigated. These results support the local verification of commercial carbapenemase PCR assays against circulating alleles before routine implementation.

Authors

Institutions

Publication Details

Journal
Diagnostics
Published
2026-11-19
DOI
https://doi.org/10.3390/diagnostics16223870
Primary Topic
Antibiotic Resistance in Bacteria
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Analytical Inclusivity of Three Commercial Real-Time PCR Platforms Against Carbapenemase Allelic Variants in Peruvian Clinical Isolates

Juan Carlos Gómez de la Torre, Luis Andres Alvarado, Maritza Elizbeth Quiroz-Reyna, Giancarlo Segundo Quiroz-Chunga et al.
Diagnostics
Antibiotic Resistance in Bacteria
article

Analytical Inclusivity of Three Commercial Real-Time PCR Platforms Against Carbapenemase Allelic Variants in Peruvian Clinical Isolates

Juan Carlos Gómez de la Torre, Luis Andres Alvarado, Maritza Elizbeth Quiroz-Reyna, Giancarlo Segundo Quiroz-Chunga, William Fernando Castillo-Aguilar
article en

Abstract

Objectives: Rapid molecular detection of carbapenemase-producing Gram-negative bacilli is crucial for targeted antimicrobial therapy, but regional gene sequence diversity can impair commercial PCR assays. This study evaluated the analytical inclusivity of three commercial real-time PCR platforms (Xpert Carba-R on the GeneXpert system, Galaxy Lite, and Molecular Mouse) against carbapenemase alleles circulating in Peru, including the regionally relevant blaIMP-74 and blaIMP-93 alleles. Methods: We analyzed a positive-enriched challenge panel of 23 non-duplicate clinical isolates previously characterized by whole-genome sequencing (WGS): 10 Enterobacterales and 13 Pseudomonas aeruginosa carrying 26 carbapenemase genes across 12 variants (blaKPC-2/35, blaNDM-1/5, blaOXA-48/181/232, blaVIM-2, and blaIMP-16/18/74/93); inclusivity was calculated per WGS-confirmed target gene, and Molecular Mouse was evaluated on a 16-target subset including at least one representative of each allele. Results: Galaxy Lite detected all carbapenemase alleles evaluated (12/12 alleles; gene-level analytical inclusivity 100%, 26/26 target genes, 95% CI: 86.8–100%). Xpert Carba-R and Molecular Mouse each detected 8 of the 12 alleles (100% of KPC, NDM, OXA-48-like, and VIM alleles), failing to detect any of the four IMP alleles evaluated. Overall gene-level inclusivity was 53.8% (14/26 target genes, 95% CI: 33.4–73.4%) for Xpert Carba-R and 62.5% (10/16 target genes, 95% CI: 35.4–84.8%) for Molecular Mouse. Conclusions: In this small, positive-enriched panel, two of the three commercial PCR panels did not detect the IMP alleles tested, a finding that may be related to primer/probe–target sequence divergence, although this mechanism was not investigated. These results support the local verification of commercial carbapenemase PCR assays against circulating alleles before routine implementation.

DiagnosticsVol. 16(22)
Universidad Ricardo Palma (PE), Forum Solidaridad Perú (PE)
Antibiotic Resistance in Bacteria
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon